Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine, Chidamide, and PD-1 Monoclonal Antibody in Refractory/Relapsed Peripheral T-Cell Lymphoma
NCT07598578Phase 1Recruiting
- Sponsor
- The Second Affiliated Hospital of Soochow University
- Start
- Jun 2026
- Primary completion
- Jan 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of azacitidine, tucidinostat and PD-1 Monoclonal Antibody in peripheral T-cell lymphoma (PTCL), sponsored by The Second Affiliated Hospital of Soochow University. Primary endpoints: Objective Response Rate at 24 months and Complete Response Rate at 24 months. Started Jun 2026; status: recruiting.
02
Drugs
azacitidinetucidinostatPD-1 Monoclonal Antibody
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT07598578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07598578.